COR vs. VRNA

Last updated Jun 9, 2026

COR (Cencora Inc.) and VRNA (Verona Pharma plc) are both stocks. Both are in the Healthcare sector — COR in Medical Distribution, VRNA in Biotechnology. At a 0.03 correlation, their price movements are largely independent.

Performance

COR vs. VRNA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Cencora Inc. (COR) and Verona Pharma plc (VRNA). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

COR

• 1D: -0.35%
• 1M: 5.22%
• YTD: -18.53%
• 6M: -18.54%
• 1Y: -4.43%
• 3Y*: 16.42%
• 5Y*: 20.49%
• 10Y*: 17.00%

VRNA

• 1D: —
• 1M: —
• YTD: —
• 6M: —
• 1Y: —
• 3Y*: —
• 5Y*: —
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

COR vs. VRNA - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
COR Cencora Inc.	-18.53%	51.48%	10.37%	25.33%	26.26%	44.09%	23.37%	23.51%	-17.57%	14.55%
VRNA Verona Pharma plc	0.00%	130.21%	133.60%	-23.92%	288.84%	-4.00%	21.74%	-40.41%	-18.71%	-12.07%

Correlation

The correlation between COR and VRNA is 0.01, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.01
Correlation (3Y) Calculated over the trailing 3-year period	-0.03
Correlation (5Y) Calculated over the trailing 5-year period	0.04
Correlation (All Time) Calculated using the full available price history since Apr 27, 2017	0.03

Fundamentals

Market Cap COR : $53.55B VRNA : $9.72B
EPS COR : $13.07 VRNA : -$0.69
PS Ratio COR : 0.16 VRNA : 57.97
PB Ratio COR : 15.76 VRNA : 34.92
Total Revenue (TTM) COR : $328.68B VRNA : $167.65M
Gross Profit (TTM) COR : $11.66B VRNA : $159.52M
EBITDA (TTM) COR : $3.64B VRNA : -$40.86M

Return for Risk

COR vs. VRNA — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

COR

COR Risk / Return Rank: 34
COR Sharpe Ratio Rank: 36
COR Sortino Ratio Rank: 31
COR Omega Ratio Rank: 31
COR Calmar Ratio Rank: 38
COR Martin Ratio Rank: 35

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

COR vs. VRNA - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Cencora Inc. (COR) and Verona Pharma plc (VRNA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	COR	VRNA	Difference
Sharpe ratio: Return per unit of total volatility	-0.15	—	—
Sortino ratio: Return per unit of downside risk	0.01	—	—
Omega ratio: Gain probability vs. loss probability	1.00	—	—
Calmar ratio: Return relative to maximum drawdown	-0.14	—	—
Martin ratio: Return relative to average drawdown	-0.39	—	—
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

Sharpe Ratios by Period

	COR	VRNA	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	-0.15	—	—
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.92	—	—
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	0.62	—	—
Sharpe Ratio (All Time) Calculated using the full available price history	0.54	—	—

Drawdowns

Drawdown Indicators

	COR	VRNA	Difference
Max Drawdown Largest peak-to-trough decline	-71.01%	—	—
Max Drawdown (1Y) Largest decline over 1 year	-32.44%	—	—
Max Drawdown (3Y) Largest decline over 3 years	-32.44%	—	—
Max Drawdown (5Y) Largest decline over 5 years	-32.44%	—	—
Max Drawdown (10Y) Largest decline over 10 years	-32.44%	—	—
Current Drawdown Current decline from peak	-26.57%	—	—
Average Drawdown Average peak-to-trough decline	-13.62%	—	—
Ulcer Index Depth and duration of drawdowns from previous peaks	11.26%	—	—

Volatility

Volatility by Period

	COR	VRNA	Difference
Volatility (1M) Calculated over the trailing 1-month period	7.05%	—	—
Volatility (6M) Calculated over the trailing 6-month period	26.87%	—	—
Volatility (1Y) Calculated over the trailing 1-year period	30.25%	—	—
Volatility (5Y) Calculated over the trailing 5-year period, annualized	22.34%	—	—
Volatility (10Y) Calculated over the trailing 10-year period, annualized	27.49%	—	—

Dividends

COR vs. VRNA - Dividend Comparison

COR's dividend yield for the trailing twelve months is around 0.86%, while VRNA has not paid dividends to shareholders.

Position	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
COR Cencora Inc.	0.86%	0.67%	0.93%	0.96%	1.13%	5.13%	6.74%	7.48%	2.07%	1.61%	1.77%	1.17%
VRNA Verona Pharma plc	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Financials

COR vs. VRNA - Profitability Comparison

The chart below illustrates the profitability comparison between Cencora Inc. and Verona Pharma plc over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

COR - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Cencora Inc. reported a gross profit of 3.59B and revenue of 78.36B. Therefore, the gross margin over that period was 4.6%.

VRNA - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Verona Pharma plc reported a gross profit of 71.68M and revenue of 75.14M. Therefore, the gross margin over that period was 95.4%.

COR - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Cencora Inc. reported an operating income of 1.14B and revenue of 78.36B, resulting in an operating margin of 1.5%.

VRNA - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Verona Pharma plc reported an operating income of 9.69M and revenue of 75.14M, resulting in an operating margin of 12.9%.

COR - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Cencora Inc. reported a net income of 1.64B and revenue of 78.36B, resulting in a net margin of 2.1%.

VRNA - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Verona Pharma plc reported a net income of 8.69M and revenue of 75.14M, resulting in a net margin of 11.6%.

Frequently Asked Questions

Can I hold both COR and VRNA in my portfolio?

COR and VRNA have a correlation of 0.01, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.